Recommendations are based on the best available evidence, about the use of trastuzumab (Herceptin®) as adjuvant therapy for the treatment of patients with HER2-positive early breast cancer and for the treatment of patients with HER2-positive metastatic breast cancer.
| اسم الملف: | herg-recommendations-trastu...st-cancer.pdf |
| حجم الملف: | 291.85 KB |
| أنواع السرطان: | سرطان الثدي |
| جمهور المنشورات: | تقارير وخطط مؤسسة السرطان في أستراليا |
| السنة: | 2007 |
| وضع المستند: | Rescinded This resource is 10 years or older and has been rescinded by Cancer Australia. It is available to the public for research and reference purposes only. Cancer Australia assumes no legal liability or responsibility for errors or omissions contained within. |